HOUSTON, Oct. 5. 2020 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting significant unmet needs in the treatment of tumors
and viruses, today announced the appointment of Elizabeth (Liz) Cermak, an accomplished life
sciences board director with deep pharmaceutical business
development expertise, to its Board of Directors.
"We are pleased to welcome Liz
Cermak, who brings nearly four decades of expertise in the
healthcare space and a proven track record of advancing clinical
development, and commercializing and licensing drugs, to our Board
of Directors," commented Walter
Klemp, Chairman and CEO of Moleculin. "We believe Liz'
extensive leadership experience in overseeing drugs through
commercialization and licensing to well-respected big
pharmaceutical companies will prove invaluable. As a highly
seasoned executive with decades of industry experience, we look
forward to Liz' counsel in driving the development of both our
oncology and infectious disease pipelines."
Elizabeth Cermak has held
numerous board positions in the healthcare space, including
currently at both Que Oncology and Clarus Therapeutics, Inc., where
she serves as an Independent Board Director. In addition, Liz was
formerly an Independent Board Director at SteadyMed Therapeutics
and served on the Board of a local non-profit, Ocean Ridge
Charities Association Inc. Previously, Liz was the Chief Commercial
Officer and Executive Vice President at POZEN, now Aralez
Pharmaceuticals. As Chief Commercial Officer at POZEN, Liz
developed the commercial strategy and launch Plans for the
Company's first self-marketed product, and signed licensing deals
with Johnson & Johnson, Desitin, and Sanofi. Prior to joining
POZEN, she worked at Johnson & Johnson for 25 years, serving
most recently as World-Wide Vice President Personal Products
Franchise and Vice President Professional Sales & Marketing,
where she was responsible for the global strategy, marketing, and
P&L for the Company's $750
million portfolio of OTC and CPG products. She also led the
$1 billion Johnson & Johnson US
Women's Health pharmaceuticals business.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
is a clinical stage pharmaceutical company focused on the
development of a broad portfolio of oncology drug candidates for
the treatment of highly resistant tumors and viruses. The Company's
clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and hematologic malignancies, and
WP1220, an analog to WP1066, for the topical treatment of cutaneous
T-cell lymphoma. Moleculin is also engaged in preclinical
development of additional drug candidates, including other
Immune/Transcription Modulators, as well as WP1122 and related
antimetabolite compounds capable of Metabolism/Glycosylation
Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to
commercialize and out-license its drug candidates. Although
Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts
James Salierno
/ Carol Ruth
The Ruth Group
973-255-8361 /
917-859-0214
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-appoints-elizabeth-cermak-to-board-of-directors-301145373.html
SOURCE Moleculin Biotech, Inc.